Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Employees

1,310

Sector

Biotechnology & Medical Research

Calendar

14/01/2025 - JP Morgan Healthcare Conference

More about the company

Quotes

Date	Price	Change	Volume
14/25/14	35.30 $	-2.00%	2,602,541
10/25/10	36.02 $	+4.41%	3,120,615
08/25/08	34.50 $	+0.85%	1,555,459
07/25/07	34.21 $	+3.04%	2,441,391
06/25/06	33.20 $	-2.27%	2,143,088

Delayed Quote Nasdaq, January 14, 2025 at 02:30 am IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart EXELIXIS-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

35.30USD

Average target price

34.93USD

Spread / Average Target

-1.06%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 14/01/2025 am IST			5-day change	1st Jan Change
35.30 ^USD	-2.00%		+3.92%	+6.01%

12/01	Exelixis Inc. Provides Earnings Guidance for Fiscal Year 2025	CI
09/01	Exelixis Says FDA No Longer Discussing Application for Cabozantinib at Committee Meeting	MT

Capitalization	1.03TCr 1.01TCr 945.56Cr 846.11Cr 1.48TCr 89TCr 1.67TCr 12TCr 4.3TCr 37TCr 3.86TCr 3.78TCr 1,62200Cr	P/E ratio 2024 *	20.4x	P/E ratio 2025 *	20.1x
Enterprise value	928.58Cr 910.38Cr 853.57Cr 763.79Cr 1.34TCr 81TCr 1.51TCr 10TCr 3.89TCr 33TCr 3.49TCr 3.41TCr 1,46400Cr	EV / Sales 2024 *	4.28x	EV / Sales 2025 *	4.13x
Free-Float	98.39%	Yield 2024 *	-	Yield 2025 *	-

Exelixis Inc. Provides Earnings Guidance for Fiscal Year 2025	13/01	CI
Exelixis Says FDA No Longer Discussing Application for Cabozantinib at Committee Meeting	09/01	MT
Exelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at Meeting	09/01	DJ
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors	09/01	CI
RBC Capital Adjusts Price Target on Exelixis to $38 From $34, Keeps Outperform Rating	30/12	MT
Exelixis Shares Decline After BMO Capital Downgrade	21/12	MT
BMO Capital Downgrades Exelixis to Market Perform From Outperform, Raises Price Target to $40 From $36	20/12	MT
Do they know it's Christmas?	20/12
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla...	20/12
Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says	17/12	MT
BofA Securities Downgrades Exelixis to Neutral, $39 Price Target	17/12	MT
Unsupported price hikes added $815 million to US drug spending in 2023	12/12	RE
Exelixis, Inc. Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 01:45 PM	05/12

RBC Capital Adjusts Price Target on Exelixis to $38 From $34, Keeps Outperform Rating	30/12	MT
BMO Capital Downgrades Exelixis to Market Perform From Outperform, Raises Price Target to $40 From $36	20/12	MT
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla...	20/12
BofA Securities Downgrades Exelixis to Neutral, $39 Price Target	17/12	MT
Analyst recommendations: Align, Nvidia, Crocs, PayPal, Reddit...	30/24/30

Exelixis, Inc. Share Price

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Valuation: Exelixis, Inc.

Chart: Exelixis, Inc.

Latest news: Exelixis, Inc.

Last Transcript: Exelixis, Inc.

Analysts' recommendations: Exelixis, Inc.

Press Releases: Exelixis, Inc.

News in other languages: Exelixis, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exelixis, Inc.

ETFs: Exelixis, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025	13/01	BU
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors	10/01	AQ
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors	09/01	BU
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025	07/01	BU
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone Payments in 2024	18/12	AQ

Merck : signe une collaboration avec Exelixis	14/24/14
Ipsen : résultats positifs du Cabometyx contre les tumeurs neuroendocrines (TNE)	16/24/16
Ipsen abandonne son projet de lancement du Cabometyx contre le cancer de la prostate	16/24/16
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Amgen, Fortinet, Moderna, Airbnb, BP...	07/24/07
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU: Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl...	04/24/04

1 day	-2.00%
1 week	+3.92%
Current month	+6.01%
1 month	+0.34%
3 months	+34.58%
6 months	+57.59%
Current year	+6.01%

Director	Title	Age	Since
Michael Morrissey CEO	Chief Executive Officer	64	22/07/2010
Christopher Senner DFI	Director of Finance/CFO	57	15/07/2015
Amy Peterson CTO	Chief Tech/Sci/R&D Officer	58	23/08/2023

Manager	Title	Age	Since
Jack Wyszomierski BRD	Director/Board Member	69	01/02/2004
George Poste BRD	Director/Board Member	80	01/08/2004
Stelios Papadopoulos CHM	Chairman	76	01/01/1998

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	13.24%	335 M€	-0.49%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	2.62%	1 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.67%	7 M€	0.00%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	1.59%	3 M€	-.--%
IQ U.S. MID CAP R&D LEADERS ETF - USD	1.30%	0 M€	+20.15%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
EXELIXIS, INC.	-2.00%	+3.92%	+55.51%	+96.55%	1.03TCr
VERTEX PHARMACEUTICALS INCORPORATED	+0.93%	+1.54%	-4.62%	+82.79%	11TCr
REGENERON PHARMACEUTICALS, INC.	+2.87%	-0.17%	-23.18%	+13.53%	7.5TCr
ARGENX SE	+0.43%	+5.58%	+87.04%	+146.31%	3.98TCr
BIONTECH SE	-7.42%	-1.77%	+9.82%	-48.50%	2.95TCr
WUXI APPTEC CO., LTD.	-0.36%	+1.53%	-25.97%	-54.52%	2.09TCr
BEIGENE, LTD.	+4.47%	+2.10%	+5.36%	-26.06%	1.88TCr
NEUROCRINE BIOSCIENCES, INC.	+1.51%	+3.57%	+8.33%	+86.99%	1.43TCr
GENMAB A/S	-2.77%	+0.90%	-27.64%	-34.74%	1.4TCr
SUMMIT THERAPEUTICS INC.	+1.82%	-0.36%	+486.29%	+651.03%	1.32TCr
Average	-0.05%	+1.78%	+57.10%	+91.34%	3.41TCr
Weighted average by Cap.	+0.51%	+0.97%	+22.84%	+66.93%

	2024 *	2025 *
Net sales	216.74Cr 212.5Cr 199.24Cr 178.28Cr 312.38Cr 19TCr 352.25Cr 2.45TCr 906.94Cr 7.69TCr 813.68Cr 796.14Cr 34TCr	221.08Cr 216.74Cr 203.22Cr 181.85Cr 318.63Cr 19TCr 359.3Cr 2.49TCr 925.08Cr 7.85TCr 829.95Cr 812.06Cr 35TCr
Net income	52Cr 51Cr 47Cr 42Cr 74Cr 4.47TCr 84Cr 581.89Cr 215.79Cr 1.83TCr 193.6Cr 189.43Cr 8.13TCr	52Cr 51Cr 48Cr 43Cr 75Cr 4.48TCr 84Cr 583.41Cr 216.36Cr 1.84TCr 194.11Cr 189.93Cr 8.15TCr
Net Debt	-100.08Cr -98Cr -92Cr -82Cr -144.24Cr -8.68TCr -162.64Cr -1.13TCr -418.76Cr -3.55TCr -375.7Cr -367.6Cr -16TCr	-114.74Cr -112.5Cr -105.47Cr -94Cr -165.38Cr -9.95TCr -186.48Cr -1.29TCr -480.13Cr -4.07TCr -430.76Cr -421.48Cr -18TCr